Convalescent Plasma Therapy Market Intelligence Report Covers Trends, Segments And Regional Growth

The convalescent plasma therapy market is gaining considerable attention as it offers promising solutions for managing infectious diseases. With ongoing advancements in medical technologies and rising preparedness for future health crises, this sector is poised for substantial growth. Let's explore the current market size, key players, emerging trends, and primary segments shaping the convalescent plasma therapy landscape.

Projected Expansion and Market Size of Convalescent Plasma Therapy
The convalescent plasma therapy market is forecasted to experience rapid growth, reaching a valuation of $0.11 billion by 2030. This expansion corresponds to a robust compound annual growth rate (CAGR) of 13.5%. Factors contributing to this upward trend include enhanced readiness for future outbreaks, improvements in antibody testing techniques, better plasma storage solutions, broader transfusion service capabilities, and ongoing research into immune-based treatments. Key market trends expected to influence development during this time include increased application in treating emerging infectious diseases, a greater emphasis on high-titer antibody plasma, growth in plasma collection infrastructure, refined donor screening and selection processes, and stronger integration with hospital-based critical care units.

The convalescent plasma therapy market size has grown rapidly in recent years. It will grow from $0.06 billion in 2025 to $0.06 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to urgent pandemic treatment demand, lack of targeted therapeutics, availability of recovered donors, emergency use authorizations, hospital-based plasma transfusion.

Download a free sample of the convalescent plasma therapy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3233&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Organizations Driving the Convalescent Plasma Therapy Market
Several prominent companies hold significant positions in the convalescent plasma therapy industry. These include Bio Farma, Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank, and Kedrion Biopharma Inc. These players are instrumental in shaping market dynamics and advancing plasma therapy innovations.

Innovations and Emerging Trends Enhancing Treatment Efficacy
Industry leaders are increasingly focusing on developing novel approaches like hyperimmune globulin therapies to boost the potency and effectiveness of convalescent plasma treatments. Hyperimmune globulin therapies utilize plasma with a high concentration of specific antibodies, sourced from recovered individuals, to deliver targeted immune support to patients suffering from infections. For example, in October 2023, Kamada Ltd., an Israeli biopharmaceutical firm, announced progress with its CYTOGAM product (Cytomegalovirus Immune Globulin Intravenous [Human]). CYTOGAM has recently become commercially available in the U.S. following FDA approval of the company's manufacturing facility in Israel. At IDWeek 2023, new clinical evidence showed a significant five-year survival advantage for high-risk lung transplant patients with CMV mismatch receiving CYTOGAM. Additionally, Kamada established its first Scientific Advisory Board to further enhance clinical programs in the U.S.

View the full convalescent plasma therapy market report:
https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Main Market Segments and Subdivisions Influencing Growth
The convalescent plasma therapy market is divided into specific segments to better understand its structure. These include:
1) Antibody Type: IgM, IgG, IgA
2) Application: Prophylaxis, Treatment
3) End Users: Hospitals and Clinics, Laboratories and Research Institutes

Within these categories, further subdivisions exist:
- IgM segment includes Early-Stage Infection Plasma and Acute Phase Plasma
- IgG segment is split into High Titer IgG Plasma and Standard IgG Plasma
- IgA segment covers Plasma Rich in IgA and Specific IgA Antibody Plasma

These segmentations help target therapies more precisely and support development efforts tailored to particular clinical needs.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.